Highest-materiality recent filing
Q2 net sales $9.5M, up 28% YoY from $7.4M; GAAP net loss $3.1M ($0.33/share) vs $3.7M ($0.44) prior year.
electroCore Q1 revenue $9.6M (+43% YoY); reaffirms ~30% FY2026 growth guidance
Net sales $9.6M, record quarterly revenue, up 43% from $6.7M Q1 2025.
electroCore FY2025 revenue $32M (+27% YoY); CEO Goldberger to retire
Revenue $32.0M, up 27% YoY; US Rx +25%, general wellness +97%.
electroCore prelim FY2025 rev $31.8-32.0M (+26%); Q4 rev ~$9.0-9.2M (+30%)
Preliminary FY2025 revenue $31.8–$32.0M, ~26% growth over FY2024 of $25.2M.
electroCore Q3 net sales $8.7M up 33% YoY; raises FY2025 revenue guidance to $31.5-$32.5M
Net sales $8.7M, 33% increase YoY; YTD net sales $22.8M, up 26% vs first nine months of 2024.
electroCore issues 360,737 shares at $5.145 to settle legal fee obligations
360,737 shares issued at $5.145 per share to settle outstanding legal fees owed to investors.
electroCore appoints Microsoft healthcare head Elena Bonfiglioli to board; declassification fails
Elena Bonfiglioli, Microsoft Global Business Leader Healthcare, appointed to board effective Sept 2, 2025.
electroCore Q2 2025 revenue up 20% to $7.4M; net loss widens to $3.7M; raises $7.2M debt
Net sales $7.4M in Q2 2025, up 20% YoY ($6.1M); YTD sales $14.1M up 22%.
electroCore amends 8-K: NeuroMetrix acquisition deemed not significant; no financials required
Filed 8-K/A on July 16, 2025 to amend the May 2, 2025 original report on the NeuroMetrix merger.
electroCore Q1 revenue up 23% to $6.7M; net loss $3.9M; guides FY25 revenue ~$30M
Q1 2025 revenue $6.7M (+23% YoY); GAAP net loss $3.9M ($0.47 loss per share).
electroCore completes acquisition of NeuroMetrix; $4.49/share plus CVRs
Cash consideration of $4.49 per NURO share; each share also gets one CVR tied to Quell sales milestones.
electroCore replaces auditor Marcum LLP with CBIZ CPAs after attest business acquisition
Marcum LLP resigned as independent registered public accounting firm on April 1, 2025; CBIZ CPAs P.C. engaged for FY 2025.
electroCore FY2024 revenue $25.2M (+57% YoY); net loss narrows to $11.9M
Full year 2024 net sales of $25.2M, up 57% from $16.0M in 2023, driven by 85% growth in VA channel and 174% increase in Truvaga.
Director Charles S. Theofilos resigns from electroCore Board; Board size reduced to seven
Charles S. Theofilos, M.D. resigned as Class III director and from Compensation and Nominating/Governance Committees effective Feb 24, 2025.
electroCore reports preliminary Q4 2024 revenue of $7.07M and FY2024 revenue of $25.2M
Preliminary net revenue for Q4 2024: $7.07 million.
electroCore to acquire NeuroMetrix in cash+CVR merger valuing NURO at net cash plus milestones
NURO shareholders receive pro rata share of net cash (min $8M condition) and one CVR per share.
electroCore enters $20M ATM offering with H.C. Wainwright
ATM agreement allows sale of up to $20M of common stock at market prices.
electroCore Q3 revenue $6.6M, +45% YoY; net loss narrows to $2.5M
Record Q3 revenue of $6.6M, up 45% from $4.5M in Q3 2023; Rx gammaCore VA/DoD sales +75% to $4.8M.
ElectroCore CFO Brian Posner retiring Oct 4, 2024; Joshua Lev appointed CFO
Posner retiring effective Oct 4 for personal/family reasons; will provide consulting services for 12 months.
electroCore Q2 net sales $6.1M (+73% YoY); net loss narrows to $2.7M
Seventh consecutive record quarterly revenue of $6.1M, up 73% YoY from $3.6M.
Director Peter Cuneo reclassified to Class I; to become consultant after 2025 board term
F. Peter Cuneo resigned as Class III director and reappointed as Class I director, term expiring at 2025 Annual Meeting.
electroCore raises $9.3M in equity/warrant offering with $5.645M from insiders
Gross proceeds of ~$9.3M from registered direct & private placements; directors/officers invested $5.645M.
electroCore Q1 net sales up 96% to record $5.4M; GAAP loss narrows to $0.53/share
Record Q1 net sales of $5.4M, up 96% from $2.8M in Q1 2023; driven by VA/DoD (+127%) and Truvaga (+162%).
electroCore reports FY2023 revenue $16.0M, up 87% YoY; Q4 revenue $5.2M, up 103%
Full year 2023 net sales of $16.0M, up 87% from $8.6M; Q4 net sales $5.2M, up 103% from $2.6M.
electroCore issues preliminary unaudited financial estimates for Q4 and FY 2023
Management will use presentation with select preliminary revenue estimates; results subject to audit and may change.
electroCore appoints Dr. Charles Theofilos to Board; board expands to eight members
Dr. Theofilos appointed as Class III director effective Dec. 8, 2023; board size increased from 7 to 8.
electroCore holds analyst day webinar on vagus nerve stimulation therapy
Analyst day webinar conducted on November 21, 2023; presentation attached as Exhibit 99.1.
electroCore Q3 2023 revenue $4.5M (+128% YoY); raises FY23 guidance to $15-15.5M
Record Q3 net sales of $4.5M, a 128% increase from $2.0M in Q3 2022.
electroCore Q2 revenue $3.6M (+65% YoY); board shrinks to 7; raises $7.5M
Record Q2 revenue $3.6M, +65% YoY; GAAP net loss $4.9M vs $5.3M prior year.
Gross proceeds to electroCore expected to be approximately $8.145 million before fees and expenses.
electroCore reports record Q2 2023 revenue of ~$3.55M, up 65% YoY
Record quarterly revenue of ~$3.55M (preliminary unaudited) for Q2 2023, +65% vs Q2 2022.
Director Joseph Errico resigns from electroCore Board, becomes Science & Strategic Advisor
Joseph P. Errico resigned from the Board and all committees on May 22, 2023; departure not due to any disagreement.
electroCore Q1 2023 net sales $2.8M (+46% YoY); GAAP net loss $5.9M; guides FY23 revenue $14-15M
Record Q1 revenue of $2.8M vs $1.9M in Q1 2022, a 46% increase across all major channels.
electroCore expects record Q1 2023 revenue of ~$2.8M, up 46% YoY
Record Q1 revenue ~$2.8M, 46% increase over $1.9M in Q1 2022.
electroCore reports record FY2022 net sales of $8.6M, up 58%; guides FY2023 revenue $14-15M
Record full-year net sales of $8.6M (+58% YoY); Q4 net sales $2.6M (+72% YoY).
Stockholders approved reverse stock split on Feb 13, 2023; implemented Feb 15, 2023.
electroCore announces 1-for-15 reverse stock split to regain Nasdaq compliance
Reverse stock split effective 12:01 a.m. ET on Feb 15, 2023; shares reduced from ~71.2M to ~4.74M.
electroCore reports record Q4 revenue of $2.5M; FY2022 revenue $8.5M, up 57% YoY
Record Q4 2022 revenue ~$2.5M (+68% YoY); full-year 2022 revenue ~$8.5M (+57% YoY).
Received Nasdaq letter on Dec 20, 2022 for failing minimum $1 bid price for 10 consecutive trading days.
Each common share receives one one-thousandth of a share of Series A Preferred; record date Dec 19, 2022.
ElectroCore annual meeting results: three directors elected, reverse split fails
Directors Goldberger, Wilber, Goldstein elected with ~83-88% of votes cast.
electroCore Q3 revenue $2.0M (+33% YoY); net loss widens to $5.5M
Q3 revenue $2.0M (+33% YoY); VA/DoD $1.15M, US Commercial $0.41M, OUS $0.37M.
electroCore Q3 2022 revenue ~$2.0M, up 33% YoY; cash $21.9M
Q3 2022 revenue approximately $1,976,000, a 33% increase over Q3 2021 revenue of $1,487,000.
electroCore sets 2022 annual meeting for Dec 2; proposal deadline Sept 30
Annual meeting to be held virtually on December 2, 2022.
electroCore Q2 2022 revenue $2.2M (+70% YoY); GAAP net loss $5.3M; gross margin 83%
Revenue $2.2M, up 70% YoY and 14% sequentially; VA/DoD $1.19M (+52.6% YoY), US Commercial $501K (+381.7%).
electroCore guides Q2 2022 revenue at least $2.1M, up 65% YoY
Record quarterly revenue of at least $2.1M, up ~65% from Q2 2021 and ~11% from Q1 2022.
Approval received June 22, 2022; transfer effective June 23, 2022 under same ticker ECOR.
electroCore assigns new directors to board committees; Goldstein to Nominating, Wilber to Audit
On May 5, 2022, Board appointed Julie Goldstein to Nominating and Corporate Governance Committee and Patricia Wilber to Audit Committee.
electroCore Q1 revenue $1.9M, up 58% YoY; net loss $5.6M
Net sales $1.9M, up 58% from Q1 2021 and 27% sequentially.
Director Michael G. Atieh resigns from electroCore board effective June 8, 2022
Michael G. Atieh, Class I director, resigns effective June 8, 2022.
the Chief Financial Officer of electroCore, Inc. (the "Company"), Brian M. Posner, informed the Board of Directors (the "Board") of the Company that he will be retiring effective as of October 4, 2024 for personal and family reasons.
the Board appointed Joshua S. Lev, as Chief Financial Officer of the Company, effective as of Mr. Posner’s retirement on October 4, 2024.
On December 8, 2023, the board of directors (the “ Board ”) of electroCore, Inc. (the “ Company ”) appointed Charles S. Theofilos, M.D., as a new Class III member of the Board.
Joseph P. Errico, a member of the board of directors (the “Board”) of the Company, resigned from the Board effective as of May 22, 2023
Trevor J. Moody, a Class II member of the Board, did not stand for reelection at the 2023 Annual Meeting of Stockholders (the “Meeting”).
On May 22, 2023, the Company and Mr. Errico entered into an amendment to Mr. Errico’s Consulting Agreement with the Company (the “Consulting Agreement”), pursuant to which Mr. Errico will serve as a Science and Strategic Advisor to the Company providing certain consulting and advisory services to the Company’s Chief Executive Officer for a three-year term.
On May 22, 2023, Joseph P. Errico resigned from the Board of Directors (the “Board”), and all committees of the Board, of electroCore, Inc. (the “Company”).
Michael G. Atieh, a Class I member of its board of directors (the “Board”) whose term lasts until the Company’s 2022 annual meeting of stockholders, is resigning from the Board effective as of June 8, 2022.
The Board accepted Dr. Ondra’s resignation effective March 4, 2022.
The newly appointed Class I members of the Board are Patricia Wilber and Julie Ann Goldstein
The newly appointed Class I members of the Board are Patricia Wilber and Julie Ann Goldstein
two current Class I members of the Board, Stephen Ondra, M.D., and Michael G. Atieh, will be resigning from the Board.
Max materiality 0.80 · Median 0.65 · Most common event earnings